POST KIDNEY TRANSPLANT PRESENTATION OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA: A CASE OF PRE-EXISTING ADAMTS13 INHIBITORS (SIE 2026) - Oct 6, 2026 - Abstract #SP011; "The aim of this abs- tract is to report a rare case of early-onset post-transplant aTTP in a patient with no prior hematological history, high- lighting the diagnostic process and the effectiveness of a multimodal therapeutic strategy including Caplacizumab (Cab)...The pa- tient's medical history was unremarkable for any known au- toimmune or hematological disorders.Immunosuppression was initiated with steroids, mycophenolate mofetil, tacroli- mus, and anti-thymocyte globulin...Treatment started with daily plasma exchange (PEX) and Rituximab (RTX), alongside adjusted baseline immunosuppression to mitigate infectious risk...This case highlights the diagnostic challenge of post-transplant aTTP and the critical importance of early ADAMTS13 assessment. The retrospective finding of pre-ex- isting inhibitors suggests that the surgical stress or induc- tion therapymay have triggered the clinical manifestation of a previously silent autoimmune state."
Clinical • Hematological Disorders • Immunology • Nephrology • Thrombocytopenic Purpura • Transplantation • HP
|
|
G. Murante1,2,3; S. Bergonzi1,2,3; M. Capetta1,2,3; F. Valeri1,2; C. Dainese1,2; A. Valpreda4; R. Pastorino1,3; F. Bocchi1,3; L. Biancone5; E. Gallo5; B. Bruno2,3; A. Borchiellini1,2
|